

Development of lead compounds for solid tumor-targeting CC12 platform-based reinforced B7H3 CAR-T cells

Seoul National University,
TiCARos, inc.



ONCOLOGY	Hit
Product Type	Gene-modified Cell
Indication	1st Indication: Solid tumor (hepatocellular carcinoma, breast cancer)
Target	B7-H3
MoA(Mechanism of Action)	B7-H3-targeting CAR T cells bind tumor cells → Proprietary T cell-strengthening gene modifications of CAR T cells eliminate tumor cells better → Enhanced CAR T cell therapy
Competitiveness	Solid tumor-targeting CAR T cells currently being developed have low-efficacy. Our group developed unique CAR T-enhancing platforms, such as Converter CAR and CLIP CAR. Composite enhancing module-equipped anti-B7-H3 CAR T cells are being evaluated for the cure of solid tumors with high-efficacy and low-toxicity.
Development Stage	Hit
Route of Administration	Parenteral-Intravenous